Pizofen

Quick links to important sections

Pizofen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pizofen

Property Description
Active ingredient Pizotifen (as Pizotifen hydrogen malate)
Form Oral formulation (Tablet or Capsule)
Pharmacological class Serotonin Antagonist and Histamine H1-Antagonist
General purpose Prophylactic treatment for recurring states of discomfort
Origin Synthetic tricyclic compound

Defining Pizofen: Drug Type and Composition

Pizofen is a prescription medicinal preparation whose sole active component is the substance Pizotifen (INN), typically presented as Pizotifen hydrogen malate. This drug is a synthetic organic compound that is structurally classified as a tricyclic compound. Unlike many over-the-counter preparations, Pizofen is a single active ingredient product, ensuring its pharmacological action is focused exclusively on the profile of Pizotifen. It is consistently supplied as an oral formulation, available in forms such as tablets or capsules, enabling systemic absorption via the oral route of administration. This form is specifically designed for ease of use in long-term, routine schedules.

Pizofen's Pharmacological Class and General Purpose

Pizofen is categorized primarily as a potent serotonin antagonist, acting mainly at the 5-HT2 receptors, and a powerful Histamine H1-receptor antagonist. This unique dual profile establishes its position as an antiserotonergic agent within its pharmacological class. By modulating the effects of key neurochemical messengers like serotonin, Pizofen's general purpose is to offer prophylactic treatment—a preventative approach—designed to stabilize certain sensitive bodily systems. This approach has been clinically recognized for its efficacy in establishing a preventative baseline against recurring vascular discomfort, distinguishing it from acute symptom-relief drugs. This function helps to manage and reduce the frequency and intensity of recurring states of discomfort related to neurovascular changes, which is its defined therapeutic role.

Regulatory References

  1. Pizotifen (IUPHAR/BPS Ligand ID: 93)

What side effects are possible with Pizofen?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of Pizotifen based on System-Organ Classes and frequency of occurrence. The core safety profile is established by effects classified as Very Common or Common.

Official Frequency Classifications

Adverse reactions are grouped according to their reported frequency in official sources:

  • Very Common (ge 1/10): Increased appetite, leading to an increase in body weight.
  • Common (ge 1/100 to <1/10): Sedation (including somnolence), dizziness, nausea, dry mouth, and fatigue.
  • Uncommon (ge 1/1,000 to <1/100): Constipation.
  • Rare (ge 1/10,000 to <1/1,000): Hypersensitivity reactions (such as face oedema), depression, anxiety, Central Nervous System (CNS) stimulation, and rash/urticaria.
  • Very Rare (<1/10,000): Seizures.

System-Organ Class and Serious Adverse Reactions

The most commonly affected System-Organ Classes are Metabolism and Nutrition Disorders and Nervous System Disorders. Other reported effects include gastrointestinal, psychiatric, and immune system disorders.

Regulatory documents also list clinically significant events. Seizures are documented as a Very Rare adverse reaction. Post-marketing reports have included serious hepatic events, such as Fulminant Hepatitis and jaundice, which are classified with a frequency of Not Known.

Safety Constraints and Special Populations

Official labeling requires specific caution for certain populations and pre-existing conditions. Dosage adjustments may be necessary for patients with Renal or Hepatic Impairment. Caution is also advised in patients with a history of epilepsy and those with a predisposition to conditions like closed-angle glaucoma or urinary retention.

A duration-related safety pattern noted in regulatory documentation is the potential for Withdrawal Symptoms following the abrupt cessation of the medicine, which include depression, anxiety, and tremors. The central sedative effects of Pizotifen may be enhanced when used concurrently with alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for Pizofen describes a risk of severe manifestations affecting multiple physiological systems, including the Central Nervous System, Cardiovascular System, and Respiratory System. Documented clinical signs include marked drowsiness, sedation, confusion, dizziness, and ataxia, alongside anticholinergic-like symptoms such as dry mouth, pyrexia, and tachycardia (rapid heart rate). Gastrointestinal signs such as nausea and vomiting may also occur.

Severe outcomes documented in regulatory labels include convulsions, coma, and respiratory paralysis. A risk of cardiorespiratory collapse is specifically noted, particularly in children. In pediatric patients, overdose may present with unique signs, including excitation, hallucinations, fixed dilated pupils, and fever.

Immediate medical attention must be sought for a suspected overdose. Regulators require contacting a physician, hospital Accident and Emergency department, or a regional Poison Control Centre immediately, even if signs of discomfort are not apparent. The mandated management is symptomatic and supportive. This includes the administration of activated charcoal and continuous ECG monitoring to evaluate cardiac risk (QRS and QT intervals). Analeptics (CNS stimulants) must be avoided, and severe hypotension must be corrected.

Regulatory documents define this profile by listing severe neurological and cardiovascular risks that necessitate immediate professional intervention. The official instructions strictly mandate urgent medical help to address the recognized potential for rapid progression to life-threatening outcomes.

Therapeutic Uses of Pizofen

What Pizofen Treats: Main Uses and Benefits

Pizofen is commonly used across therapeutic domains where patients experience symptoms related to recurrent vascular headaches, including typical and atypical migraine, vasomotor headache, and cluster headache. This medication is considered relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain.


Therapeutic Support and Symptom Management

The core therapeutic benefit is relevant for easing the overall symptom load by helping to manage symptoms related to acute or episodic changes. It is commonly used for managing symptom clusters that may become intense or disruptive in both adults and older children/adolescents. This preventative approach supports the management of symptom clusters that may become intense or disruptive, offering symptomatic relief that contributes to improved comfort during periods of heightened symptoms. This may help patients cope more steadily with symptom fluctuations, providing support that helps ease the overall symptom burden when recurrent episodes create noticeable functional strain.


Quick Fact: Support for Symptoms Related to Physical Discomfort

Pizofen is applied across domains involving episodic or fluctuating manifestations where symptoms related to physical discomfort are pronounced, offering supportive relief for conditions characterized by heightened symptoms.


Regulatory References

  1. New Zealand Medicines and Medical Devices Safety Authority (Medsafe)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Pizofen — Official Regulatory Information

Scope Item Official Regulatory Status
Populations Allowed Adults and Adolescents (12-17 years) are generally approved for use. Children from 2 years of age are included in the indication in some regions.
Populations Not Recommended Nursing/Lactating mothers are advised that use is generally not recommended. Children below two years of age should not be given the medicine.
Absolute Contraindications Patients with known hypersensitivity to Pizotifen or any excipient. Patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing such therapy. Patients with pyloroduodenal obstruction or certain hereditary metabolic disorders. Children under 12 years of age are contraindicated in certain jurisdictions.

Age-Related Eligibility and Restrictions

  • Adults have established use for prophylactic treatment.
  • Older Adults (65 years and above) require caution due to the frequent presence of concurrent dysfunctions (hepatic, renal, etc.).
  • Children under 12 are prohibited in some regions, while use is permitted from 2 years of age in others.

Condition-Specific Cautions

  • Caution is required for patients with renal impairment or hepatic impairment, as dosage adjustments may be necessary, and treatment may need to be discontinued if liver dysfunction develops.
  • Use with caution is also required for individuals with conditions such as narrow-angle glaucoma, a predisposition to urinary retention, or a history of epilepsy.

Reproductive Status Limitations

  • Pregnancy: Safety has not been established. Use is only permitted if the potential benefit to the mother justifies the potential risk to the fetus, due to limited clinical data.
  • Lactation: Use of Pizofen is not recommended while breastfeeding.

What should I know about interactions with other medicines?

The official regulatory profile for Pizofen establishes several specific interaction categories based on its documented pharmacological and metabolic activities.

The most restrictive constraint is the formal prohibition against concomitant use with Monoamine Oxidase Inhibitors (MAOIs), which is classified as a contraindicated combination. Regulatory documents mandate a strict 14-day separation window (washout period) before Pizofen can be administered following MAOI therapy.

Pharmacodynamic interactions are defined by the drug's effect on the central nervous system. Co-administration with other CNS depressants, such as sedatives, hypnotics, or antihistamines, may lead to the enhancement of central effects, including increased drowsiness and dizziness. Furthermore, Pizofen is documented to antagonise the hypotensive effects of adrenergic neurone blockers.

The pharmacokinetic interaction profile relates to Pizotifen’s extensive metabolism via N-glucuronidation. Regulatory data state that an increased plasma concentration of Pizotifen cannot be excluded when co-administered with medicines that exclusively undergo this metabolic route. Regarding substances, the official labeling advises that the use of alcohol should be avoided, as it can enhance the central depressant effects. Finally, caution is specifically noted for patients with hepatic or renal impairment due to the possibility of accumulation of the parent drug or its metabolites.

Mechanism of Action

Modulation of the Neurovascular System via Receptor Blockade

Pizotifen acts as an antagonist (blocker) at the Serotonin mathbf5- HT2A/2C and Histamine mathbf H1 receptors. By preventing these endogenous mediators from binding to their targets, the drug reduces the interaction of mediators that trigger vascular hyper-reactivity and increase plasma protein extravasation (leakage) in the microvasculature. This mechanism contributes to modulating the vascular baseline and restricts the signaling capable of initiating a neurogenic inflammatory cascade.

Preventative Style of Pathway Modulation

The collective impact of this broad receptor blockade is a preventative style of modulation of pathways that regulate vascular tone and tissue sensitivity. By targeting the early molecular steps involving both Serotonin and Histamine, Pizotifen prevents the initiation of these signaling sequences. This mechanism requires sustained engagement with the target receptors, resulting in a delayed functional change and lacking the speed required for an acute physiological response.

Dosage and Administration Information

How to Use Pizofen: Official Administration Guidelines

Pizofen (Pizotifen) is administered via the oral route as a daily, consistent schedule for prophylactic use, rather than for the relief of acute symptoms. The medication is available as tablets, capsules, and an oral liquid, and must be taken regularly to maintain its preventive effect.


Standard Dosing and Frequency

The administration of Pizotifen typically follows a titrated schedule, starting at a low dose and gradually increasing as needed for efficacy:

  • Adult Starting Dose: Usually 0.5 mg once daily.
  • Adult Maintenance Dose: Generally 1.5 mg daily, which can be taken as a single dose or divided into three doses.
  • Maximum Daily Dose: The dosage may be increased up to 4.5 mg daily in refractory cases, taken in divided doses.

The dose is often taken as a single dose at night to align with the recommendation to minimize potential daytime drowsiness. The medicine can be taken with or without food.


Administration and Procedural Rules

Instruction Detail
Ingestion Constraint Tablets must be swallowed whole and must not be crushed or chewed.
Pediatric Use Not recommended for children under 2 years. For older children, the maximum daily dose is 1.5 mg.
Cessation Procedure Treatment requires gradual withdrawal (dose reduction) upon discontinuation to minimize the risk of rebound symptoms.
Missed Dose Do not take a double dose to compensate for a missed dose; continue with the next scheduled time.

These official instructions define the required oral route, the specific titration limits, and the timing conditions that guide the standardized, prophylactic application of Pizofen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pizofen

Evidence for use in Migraine Prophylaxis

Research has explored Pizofen in conditions characterized by fluctuating manifestations, specifically examining its application for migraine headache prevention in adults. The available evidence primarily consists of short-term randomized controlled trials (RCTs). These studies were designed to measure outcomes related to physical discomfort, such as the number of headache days per month and their intensity, alongside patient-reported outcomes describing perceived discomfort. Research reports that populations receiving Pizofen had patterns of measured change during the study period related to headache frequency, compared to those receiving a placebo or a different medication. However, findings were mixed across research settings.

Long-term Studies and Follow-up

Research has been conducted primarily over short time intervals, and follow-up durations were limited across the existing body of evidence. Studies monitoring outcomes over extended time frames are not fully established. What is known about longer-term patterns comes mainly from observational settings, which provide limited insight into long-term symptom activity. Because long-term effects are not fully established, there is limited information for long-term outcomes.

Evidence in Special Populations

Specific research on Pizofen has evaluated its application in select groups beyond the general adult population, including studies that have explored its application in children and adolescents. Data for certain groups remain insufficient, and research is ongoing to explore its application in older adults. Similarly, for patients with comorbid conditions, such as those with pre-existing kidney or liver issues, available data remain insufficient.

Investigational Areas and Other Outcomes Examined

Beyond its primary indication studied, Pizofen was observed in some studies that examined other physiological responses. Research explored outcomes related to weight changes because studies monitored reports of appetite shifts in some patient groups. These data show patterns related to non-target effects observed in research scenarios.

What is Still Uncertain about Pizofen

The overall evidence landscape suggests that certainty remains low in several key areas. Research exploring short-term symptom changes provides an initial view, but certain groups, such as special populations, lack sufficient data. Comparative evidence is lacking to definitively understand how Pizofen's observed patterns differ from all other available options. Key limitations include that sample sizes were modest in many studies, and evidence quality varies across studies.

Key Studies & References

  1. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION: SANDOMIGRAN DS Pizotifen tablets (Regulatory Document covering special populations and safety)

Frequently Asked Questions (FAQ)

Common questions about Pizofen (FAQ)

Q: What is the main medical condition Pizofen is approved to treat?

A: According to official regulatory documents, Pizofen is approved for the prophylactic treatment of recurrent vascular headaches.

This means its primary use is for the prevention and reduction of the frequency of specific headache types, such as classical migraine, common migraine, and cluster headaches.


Q: Is Pizofen considered a long-term treatment option?

A: Pizofen is a preventative medicine that is intended to be used on a daily, consistent schedule.

Official medical guidance indicates that it can be used for long-term preventive treatment under the direction of a healthcare professional.


Q: How long does Pizofen typically take to start showing its desired effect?

A: Studies and official information indicate that the full therapeutic response from Pizofen is not immediate.

Because it works preventatively, it can take several weeks of therapy to notice its effects. Regulatory documents suggest a trial period of up to a few months may be necessary to properly assess its efficacy.


Q: Is Pizofen used to treat multiple different issues or symptoms?

A: Yes, regulatory labels show that Pizofen is used for the prevention of more than one type of vascular headache.

This includes the prevention of classical migraine, common migraine, and cluster headaches, which also includes tension headaches in its scope.


Q: Is it safe to use Pizofen while driving or operating machinery?

A: Due to the potential for drowsiness, sedation, and dizziness as common side effects, official labels caution against driving or operating heavy machinery.

Individuals are generally advised to wait until they know precisely how the medicine affects them before performing hazardous tasks.


Q: Can Pizofen affect normal sleep patterns or cause insomnia?

A: While Pizofen commonly causes drowsiness, official side effect listings also note that it can affect sleep in other ways.

Insomnia (difficulty sleeping) and general problems sleeping are documented as possible effects, particularly if the medicine is stopped abruptly.


Q: Are there any required dietary restrictions when someone is taking Pizofen?

A: Pizofen can be taken with or without food. There are no specific food restrictions mentioned in official regulatory documents.

However, alcohol is noted as a substance to be avoided, as it can increase the drug's central depressant effects like drowsiness.


Q: What are the signs of a severe allergic reaction to Pizofen that require attention?

A: Signs of a potentially serious allergic reaction are listed in the regulatory safety information.

These may include a generalized rash or hives, swelling of the face, lips, tongue, or throat, difficulty breathing, and severe dizziness. If any of these signs appear, seeking immediate medical review or attention is advised.


Q: Is it normal to feel a mild headache or upset stomach after first starting Pizofen?

A: Yes, official safety information indicates that some individuals may experience side effects such as headache and nausea (feeling sick).

Dyspepsia, or general upset stomach, is also noted as a common effect when first starting the medicine.


Q: Are there any reported long-term health risks associated with extended Pizofen use?

A: Regulatory documents include warnings about potential health risks associated with prolonged use.

Official guidance advises that hepatotoxic effects (damage to the liver) and severe hepatitis have been reported. For this reason, periodic monitoring of liver function may be recommended during extended therapy.


Q: Why is Pizofen often started at a low amount?

A: The administration schedule often starts at a low amount and increases gradually, which is known as titration.

This gradual approach is used to minimize potential central nervous system side effects such as drowsiness. It also helps to ensure the individual is taking the lowest effective dose for their needs.


Q: How long do the initial or temporary side effects of Pizofen usually last?

A: Official regulatory documents do not provide a specific time frame for how long initial side effects typically last.

If any effect lasts for an extended period or seems to be getting worse, consultation with a healthcare professional is suggested.


Q: What general information is available regarding accidental overdose of Pizofen?

A: Official safety materials recommend immediate contact with a doctor or poison control center.

In situations requiring urgent care, regulatory guidance suggests going to the nearest hospital’s Emergency Department.


Q: Is Pizofen safe for people with a history of heart issues?

A: Official regulatory guidance advises that Pizofen should be used with caution in patients who have a history of cardiovascular disease (heart issues).

The treating physician determines if the potential benefits outweigh any possible risks.


Q: Does taking Pizofen require regular lab tests or monitoring?

A: Yes, official guidance recommends that individuals taking Pizofen for a prolonged period undergo periodic evaluation of liver function.

This testing is recommended because of the documented risk of liver injury (hepatotoxicity) in the regulatory safety information.


Q: Can I take Pizofen with flu or cold medicine?

A: Regulatory labels caution that Pizofen may interact with certain medications found in common flu or cold preparations.

Specifically, interactions can occur with Central Nervous System (CNS) agents, such as antihistamines, which may enhance central effects like drowsiness.


Q: Is it possible to be resistant to Pizofen's effects?

A: Patient information published in regulatory materials indicates that the medicine may not work as well if it is used for a very extended period.

If there is a perceived reduction in efficacy, consulting a healthcare provider is suggested for a review of the treatment plan.


Q: Are there different brand names for Pizofen?

A: Yes, Pizofen is the name of the active ingredient in the medicine.

Depending on the country or region, this active ingredient may be sold under several different brand names, such as Sandomigran.

How should Pizofen be stored and disposed of?

How to Store and Dispose of Pizotifen

Official regulatory labeling dictates specific conditions for the storage and disposal of Pizotifen to maintain product stability and ensure safety.

Storage Requirements

Storage Component Official Requirement
Temperature Store at controlled room temperature, typically below 25°C (or 30 C for some regional formulations).
Protection Must be protected from light and moisture; do not freeze or refrigerate.
Packaging Keep the medicine in its original container until use.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Pizotifen must not be disposed of in household waste or flushed down a toilet. The medicine should be discarded according to local regulations for pharmaceutical waste handling, often by returning it to a pharmacist or a designated medicine collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pizofen found in:

A-Z Index: